SCHEMBL2438158

SCHEMBL2438158

Cc1cc(C(=O)Nc2ccc(Oc3ccc(Cl)cc3)cc2)c(C)n1-c1ccccc1C(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.59
NPSR1 Q6W5P4 2/20 0.59
MAPK1 P28482 2/20 0.59
PNLIP P16233 5/20 0.49
NR3C2 P08235 2/20 0.48
TLR8 Q9NR97 2/20 0.48
ALDH1A1 P00352 3/20 0.47
LMNA P02545 3/20 0.47
RAB9A P51151 3/20 0.47
HPGD P15428 2/20 0.47
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
ALOX12 P18054 1/20 0.44
POLB P06746 2/20 0.43
STK39 Q9UEW8 2/20 0.43
GAA P10253 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383390 0.94 MAPT (0.66) MAPTNPSR1MAPK1NR3C2ALDH1A1
SCHEMBL1378764 0.93 ALDH1A1 (0.53) MAPTNPSR1MAPK1PNLIPNR3C2
SCHEMBL1382556 0.88 RAB9A (0.51) MAPTNPSR1MAPK1PNLIPALDH1A1
SCHEMBL1378238 0.87 P2RY1 (0.51) MAPTNPSR1MAPK1ALDH1A1LMNA
SCHEMBL1380343 0.86 MAPT (0.49) MAPTNPSR1MAPK1PNLIPNR3C2
SCHEMBL1380344 0.86 MAPT (0.54) MAPTNPSR1MAPK1NR3C2ALDH1A1
SCHEMBL2442539 0.85 MAPT (0.57) MAPTNPSR1MAPK1NR3C2ALDH1A1
SCHEMBL2028524 0.85 LMNA (0.48) MAPTNPSR1MAPK1NR3C2ALDH1A1
SCHEMBL1380193 0.85 RAB9A (0.51) MAPTNPSR1MAPK1ALDH1A1LMNA
SCHEMBL1378243 0.85 CNR1 (0.48) MAPTNPSR1MAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 MAPT 2014/4885NPSR1 4/4885MAPK1 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.